Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nucleolar RNA host gene 20 (SNHG20) is a long non-coding RNA of 2183 nucleotides, located on chromosome 17q25.2, and serves as an oncogenic regulator in multiple human cancers. SNHG20 is typically upregulated in tumor tissues and is associated with advanced disease stage and poor patient prognosis. Mechanistically, SNHG20 promotes cell proliferation and inhibits apoptosis by binding to EZH2 (a core component of PRC2), resulting in epigenetic silencing of tumor suppressor gene P21, and also affects other cell cycle and proliferation markers such as PCNA and Ki-67. It may also interact with or regulate other genes and microRNAs (e.g., STAT3, miR-495, DDX17). There are currently no approved drugs directly targeting SNHG20, but it is considered a promising future target for cancer diagnostics and therapeutics.
Epigenetic silencing via interaction with EZH2 leading to repression of P21 transcription; Competing endogenous RNA (ceRNA) mechanism (regulation of DDX17, miR-495, STAT3)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nucleolar RNA host gene 20 (SNHG20).